{"disease":{"id":"pancreatic-ductal-adenocarcinoma-pdac","name":"pancreatic ductal adenocarcinoma pdac"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06122896","title":"Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06151223","title":"A Prospective Registry for Patients at High-Risk for Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04605237","title":"Pancreatic Cancer Recurrence in the Netherlands","phase":"","overall_status":"UNKNOWN","enrollment_count":1750,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT07516392","title":"Study of a Polygenic Risk Score to Predict the Risk of Pancreatic Ductal Adenocarcinoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1140,"lead_sponsor_name":"Catholic University of the Sacred Heart","has_results":false},{"nct_id":"NCT06445062","title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":1130,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT07224750","title":"A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05379985","title":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":754,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT04622423","title":"Advanced Therapies for Liver Metastases","phase":"","overall_status":"RECRUITING","enrollment_count":625,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT06040541","title":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":604,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT07252232","title":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT07241676","title":"Early Recurrence After Surgery for Pancreatic Cancer","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":500,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT07329920","title":"Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Guo ShiWei","has_results":false},{"nct_id":"NCT07223047","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06710132","title":"Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":false},{"nct_id":"NCT06895031","title":"Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"Guangzhou JOYO Pharma Co., Ltd","has_results":false},{"nct_id":"NCT07217717","title":"Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"SOFIE","has_results":false},{"nct_id":"NCT07036978","title":"Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT03549000","title":"A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04883450","title":"PRedictiOn Algorithms for the DeTECTion of Early Stage Pancreatic Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":126,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT07435038","title":"Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Betta Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT07144917","title":"Immunoparalysis After Pancreaticoduodenectomy","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06044064","title":"\"Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)\" - A Prospective Pilot Observational Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Asian Institute of Gastroenterology, India","has_results":false},{"nct_id":"NCT07373691","title":"A Study on Multimodal Prognostic Scoring of Advanced PDAC.","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT07301229","title":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT04575363","title":"RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT07444840","title":"How Does Pre-operative Biliary Drainage in Pancreatic Adenocarcinoma Affect Surgical Outcomes in Pancreatic Cancer Surgery","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"East Lancashire Hospitals NHS Trust","has_results":false},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT05441189","title":"Precise Gene Signature for Predicting Outcomes in PDAC","phase":"","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"The Fourth Affiliated Hospital of Anhui Medical University","has_results":false},{"nct_id":"NCT06720454","title":"Study on Single-cell Regulons Atlas of Pancreatic Ductal Adenocarcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Tiejun Ying","has_results":false},{"nct_id":"NCT04990609","title":"EUS-RFA PANCARDINAL-1 Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"The University of Texas Health Science Center, Houston","has_results":false},{"nct_id":"NCT07303465","title":"To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Ranok Therapeutics (Hangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT03032913","title":"Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC","phase":"","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT05168254","title":"Clinical and Multiomics Study of First-line Chemotherapy for Advanced Pancreatic Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06616688","title":"Innovative Therapeutic Treatments to Inhibit Perineural Invasion in Pancreatic Adenocarcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT06182072","title":"ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"ProDa BioTech, LLC","has_results":false},{"nct_id":"NCT03767582","title":"Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT07235202","title":"A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Shenzhen Majory Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT07480928","title":"Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT06361030","title":"Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT06659705","title":"Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT05201729","title":"Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT07114861","title":"The KN510713 Study in Combination With mFOLFIRINOX","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"New Cancer Cure-Bio Co.,Ltd.","has_results":false},{"nct_id":"NCT03727880","title":"Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Lei Zheng","has_results":true},{"nct_id":"NCT06967662","title":"Selective Plasma Adsorption of Extracellular DNA in Prevention of Intraoperative Metastasis in Pancreatic Cancer (Pilot Study)","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":28,"lead_sponsor_name":"Ilyinskaya Hospital, JSC","has_results":false},{"nct_id":"NCT06147154","title":"Microbiota and Metabolites Alterations in Pancreatic Head and Body/Tail Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT07014254","title":"Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT05605522","title":"A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"3B Pharmaceuticals GmbH","has_results":false},{"nct_id":"NCT05642962","title":"Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":17,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06599502","title":"A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07030283","title":"Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"University of Colorado, Denver","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}